ERBB2 and breast carcinoma: Some studies of inetetamab in various circumstances are ongoing: inetetamab for advanced breast cancer (ABC) in combination with PD-1 inhibitor (NCT05291910) or pyrotinib (NCT05856383, NCT05823623, and NCT04681911) or pertuzumab (NCT05749016), inetetamab in combination with pyrotinib in HER2 mutant or amplified advanced NSCLC (NCT05016544), among others.